OOT HARDCORE 3HP CHALLENGE! ATTEMPT #4 CONTINUES - Celebrating OOT Remake - !3HP, !discord, !bluesky | Streaming the legend of zelda: ocarina of time.

Treatment of tuberculosis infection (TBI) is a key pillar of the World Health Organization End TB Strategy. Two short-course rifamycin-based regimens—3 months of weekly isoniazid plus rifapentine (3HP) and 4 months of daily rifampicin (4RIF)—are widely recommended; however, they have not previously been directly compared in a randomized controlled trial. We compared treatment completion between 3HP and 4RIF among individuals with TBI.MethodsWe conducted a multicenter, open-label, parallel-group randomized controlled trial across 7 tuberculosis clinics in Sydney, Australia, between July 2019 and June 2024. Participants of any age with TBI were randomized 1:1, stratified by site, to receive either weekly 3HP or daily 4RIF. All doses were self-administered. Participants in the 3HP group received weekly Short Message Service (SMS) adherence reminders; both groups received standard clinic follow-up. The primary outcome was treatment completion, defined as ingestion of ≥90% of prescribed doses. Analyses were conducted on an intention-to-treat basis.ResultsA total of 210 participants were enrolled (106 assigned to 3HP and 104 to 4RIF). Treatment completion was significantly higher in the 3HP group (84.9%) than in the 4RIF group (65.4%; relative risk, 1.30 [95% confidence interval, 1.22–1.38]; P < .001). Adverse events of any grade occurred in 24.5% of participants receiving 3HP and 20.2% receiving 4RIF. No treatment-related deaths were reported.ConclusionsWeekly 3HP supported by SMS reminders achieved significantly higher treatment completion than daily 4RIF, with similar safety. These findings support broader implementation of 3HP to optimize adherence and outcomes in TBI treatment programs.Clinical Trials RegistrationAustralian New Zealand Clinical Trials Registry (ACTRN12618001672246).

The safety of a 3-month weekly rifapentine-isoniazid (3HP) for tuberculosis prevention in HIV-positive pregnant women on antiretroviral treatment is unknown. As part of the WHIP3TB trial, 3HP administered once or annually for 2 years was compared to 6 months of isoniazid. We report outcomes among women who became pregnant, with drug exposure in early pregnancy.MethodsWomen were classified as exposed if conception occurred while taking study drug, and unexposed if conception occurred after the last dose. Outcomes included live birth, stillbirth, or abortion. A composite adverse pregnancy outcome was defined as any of the following: stillbirth, spontaneous abortion, low birth weight (<2500 g), preterm delivery (<37 weeks’ gestation), or major congenital anomalies. Outcomes were compared between exposed and unexposed groups.ResultsAmong 2207 women aged 15–49 years enrolled between November 2016 and November 2017, 236 pregnancies occurred in 222 participants. Fifty-seven (24%) were exposed to study drug (51 in 3HP arm, 6 in 6 months of isoniazid arm) and 179 were unexposed. Median age was 32 years, median antiretroviral treatment duration 2.9 years (interquartile range; 1.2–4.9 years) and median CD4 count 522 cells/L; [interquartile range, 345–684). Of 219 pregnancies with known outcomes, 162 (74%) were live births, 51 (23%) abortions, and 6 (3%) stillbirths. Spontaneous abortions occurred at similar frequencies among exposed (12% [7/57]) and unexposed (14% [22/162]) groups with comparable rates of composite adverse outcomes (33% [19/57] vs 35% [56/162]).ConclusionsSpontaneous abortion and composite adverse pregnancy outcomes following first-trimester exposure to 3HP were comparable between exposed and unexposed groups, supporting the safety of 3HP in pregnancy.

💰 De: R$ 769,00 🔥 Por: R$ 436,00 • 🏷️ 43% de desconto • 🛍️ Loja: Mercado Livre

OOT HARDCORE 3HP CHALLENGE! ATTEMPT #3 CONTINUE - Celebrating OOT Remake - !3HP, !discord, !bluesky | Streaming the legend of zelda: ocarina of time.

OOT HARDCORE 3HP CHALLENGE! ATTEMPT #3 CONTINUE - Celebrating OOT Remake - !3HP, !discord, !bluesky | Streaming the legend of zelda: ocarina of time.

シュウ「好時節」Lv.1Lv.2Lv.3HP攻撃力防御力素質【天に四時あり】編成中に【歳】が4名以上いる場合、全ての味方オペレーターの攻撃力+12%、SPを4秒ごとに1回復配置中、戦場にいる味方オペレーターの職業が3種類以上となる場合、全て...

OOT HARDCORE 3HP CHALLENGE! ATTEMPT #2 START! - Celebrating OOT Remake - !3HP, !discord, !bluesky | Streaming the legend of zelda: ocarina of time.

OOT HARDCORE 3HP CHALLENGE! Celebrating OOT Remake - !3HP, !discord, !bluesky | Streaming the legend of zelda: ocarina of time.

₹9,999.00 (was ₹44,999.00) · 78% off · Amazon India

The WELLFIT TM037 Halloween Edition is a compact, quiet treadmill with 0–5% incline, sturdy handrails, and speeds up to 6.2 mph. It features a 3HP brushless motor, free APP access, 3D VR routes, and A...

Background: Young children with exposure to or infection with are at high risk of developing tuberculosis disease, and postexposure tuberculosis preventive treatment decreases this risk. Evidence is limited regarding the dosing and safety of the 12-dose once-weekly rifapentine and isoniazid regimen (3HP) for tuberculosis preventive treatment in children younger than 2 years and in children living with HIV. Objective: This #Protocol describes Tuberculosis Trials Consortium (TBTC) #Study 35, which aims to establish practical age- and weight-banded rifapentine doses for 3HP in children aged 0 to 12 years, including children younger than 2 years, and children living with HIV, while assessing safety, tolerability, palatability, and acceptability. Methods: TBTC #Study 35 was a phase I/II, open-label, multisite, single-arm, exposure-controlled dose-finding and safety #Study of 3HP in children aged 0 to 12 years, including children living with HIV. Novel water-dispersible rifapentine and isoniazid formulations were used. Building on TBTC #Study 26 data, initial rifapentine doses were selected, and nonlinear mixed-effects modeling was used to analyze the pharmacokinetic data and evaluate subsequent rifapentine doses. Safety was monitored throughout the 12-week treatment period and 12-week posttreatment follow-up. Results: Data collection began with the first recruitment in November 2019. The last participant was enrolled in December 2023, and participant follow-up and data collection were completed in May 2024. As of now, 69 participants were enrolled. The trial was funded throughout this time period. Data analysis is ongoing, and trial results are expected to be disseminated in 2026. Conclusions: TBTC #Study 35 is expected to provide pharmacokinetic and safety data to inform practical pediatric 3HP dosing recommendations, including for children younger than 2 years and children living with HIV. Trial Registration: ClinicalTrials.gov NCT03730181; https://clinicaltrials.gov/#Study/NCT03730181 International Registered Report Identifier (IRRID): RR1-10.2196/103274

YouTube video by Mr Typer

YouTube video by Global News